← Leaderboards
Steven D. Townsend
Vanderbilt University
$2,926,078
Attributed
$3,301,001
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $836.4K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,301,001 · 2
By mechanism
R35$2,551,154 · 1
R01$749,847 · 1
Top collaborators
- Jennifer A Gaddy2 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Laurence J Zwiebel$9,792,749
- Maria Hadjifrangiskou$5,894,528
Others in their field
Other Emerging Leaders on “Human Milk”
- Akila Subramaniam · University Of Alabama At Birmingham$6,547,544
- Jillian Pintye · University Of Washington$4,946,781
- Michiko Oyoshi · Boston Children'S Hospital$4,595,561
- Yeyi Zhu · Kaiser Foundation Research Institute$4,310,450
- Rebecca Powell · Icahn School Of Medicine At Mount Sinai$3,892,293
- Maria A Curotto De Lafaille · New York University School Of Medicine$3,793,314
Research focus
Human MilkMicrobiomeProgramsPublic HealthCellsOligosaccharidesPermeabilityPathogenAntibioticsChemistryInfectionMicrobial BiofilmsAntimicrobialMembraneNovel StrategiesGlycopeptidesGram-Negative BacteriaBiochemistryCombatFoundationsBacteriaBehaviorGram-Negative Bacterial InfectionsGrowth
Grant awards (11)
Bioorganic Approaches Toward Novel Antimicrobial Agents and Chemotherapeutics$451,462
R35 · FY2025 · GM · contact PI
Utility of human milk oligosaccharides against the perinatal pathogen, Group B Streptococcus$364,926
R01 · FY2025 · HD
Bioorganic Approaches Toward Novel Antimicrobial Agents and Chemotherapeutics$451,462
R35 · FY2024 · GM · contact PI
Utility of human milk oligosaccharides against the perinatal pathogen, Group B Streptococcus$384,921
R01 · FY2024 · HD
Bioorganic Approaches Toward Novel Antimicrobial Agents Against Gram-Negative Bacteria$299,528
R35 · FY2023 · GM · contact PI
Bioorganic Approaches Toward Novel Antimicrobial Agents Against Gram-Negative Bacteria$83,067
R35 · FY2023 · GM · contact PI
Bioorganic Approaches Toward Novel Antimicrobial Agents Against Gram-Negative Bacteria$299,528
R35 · FY2022 · GM · contact PI
Bioorganic Approaches Toward Novel Antimicrobial Agents Against Gram-Negative Bacteria$69,223
R35 · FY2022 · GM · contact PI
Bioorganic Approaches Toward Novel Antimicrobial Agents Against Gram-Negative Bacteria$299,528
R35 · FY2021 · GM · contact PI
Bioorganic Approaches Toward Novel Antimicrobial Agents Against Gram-Negative Bacteria$298,678
R35 · FY2020 · GM · contact PI
Bioorganic Approaches Toward Novel Antimicrobial Agents Against Gram-Negative Bacteria$298,678
R35 · FY2019 · GM · contact PI